购物车
- 全部删除
- 您的购物车当前为空
Crovalimab (SKY59; RO7112689)是一种人源化抗C5抗体,其通过pH依赖性机制发挥作用,其KD值在pH 7.4时为15.2nM,在pH 5.8时为16.8μM。该化合物还以高亲和力结合于人FcRn(KD: 17μM; pH 6.0)。通过阻断C5转化酶对C5的切割及抑制C5变体(p.Arg885His)的活性,Crovalimab能够显著抑制补体系统中经典途径(CP)、凝集素途径(LP)以及旁路途径(AP)中C5b-9的形成。因此,Crovalimab展现出作为研究阵发性睡眠性血红蛋白尿(PNH)及其他补体介导疾病的潜力。
Crovalimab (SKY59; RO7112689)是一种人源化抗C5抗体,其通过pH依赖性机制发挥作用,其KD值在pH 7.4时为15.2nM,在pH 5.8时为16.8μM。该化合物还以高亲和力结合于人FcRn(KD: 17μM; pH 6.0)。通过阻断C5转化酶对C5的切割及抑制C5变体(p.Arg885His)的活性,Crovalimab能够显著抑制补体系统中经典途径(CP)、凝集素途径(LP)以及旁路途径(AP)中C5b-9的形成。因此,Crovalimab展现出作为研究阵发性睡眠性血红蛋白尿(PNH)及其他补体介导疾病的潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 询价 | 期货 |
产品描述 | Crovalimab (SKY59; RO7112689) is a novel humanized antibody designed to target C5 in a pH-dependent manner, demonstrating binding affinities (KD) of 15.2 nM and 16.8 μM at pH levels of 7.4 and 5.8, respectively. Additionally, it shows high affinity for human FcRn at pH 6.0, with a KD of 17 μM. By blocking C5 cleavage by C5 convertase and inhibiting the activity of a C5 variant (p.Arg885His), Crovalimab effectively prevents the formation of C5b-9 across the classical (CP), lectin (LP), and alternative (AP) complement pathways. This characteristic highlights its potential utility in research concerning paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases. |
CAS No. | 1917321-26-6 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.